Scott is a senior healthcare executive with in-depth experience with medical device, pharmaceutical and healthcare services opportunities.

He is also a partner with Eastmont Partners, LLC, a healthcare management consulting and private investment firm, where he has consulted for some of the world’s leading healthcare-oriented private equity and venture capital firms, as well as leading academic medical institutions.

Prior to founding GI Scientific and Eastmont, he co-led the corporate development/M&A teams at Covidien PLC, now Medtronic PLC.  Before Covidien, he worked in the strategy and corporate development group at Edwards Lifesciences, and before Edwards, he practiced law at the international law firm of Paul, Hastings, Janofsky & Walker LLP.  Prior to practicing law, he served as the acting Chief Financial Officer for H-3 Systems, an Apple Computer-backed networking software start-up, and he began his career with Weyerhaeuser Company’s corporate venture capital unit.

He holds a M.B.A. from the UCLA Anderson School of Management, a J.D. from Loyola Law School and a B.A. from the University of California, Irvine.

Michael is President of The Enterprise Group Ltd, a strategic healthcare investment and advisory firm working with mid-market health care and tech-enabled services companies and private equity funds. Previously, he served as a senior advisor to Centerbridge Partners. Michael also serves on the Boards of American Renal Associates (NYSE: ARA), GI Scientific and Clever Care Health Plan. Previous Board service includes, Remedi Senior Care, Versant Health (fka Superior Vision Corp) and Genesis Healthcare (fka as Skilled Healthcare Group).

Previously, Michael served as the Chief Financial Officer of HealthMarkets, Inc., a provider of health and life insurance products. Michael was Chief Financial Officer of Mariner Health Care, Inc., a skilled nursing facility and long-term acute care provider. Michael served as Chief Financial Officer of Allergan plc (formerly Watson Pharmaceuticals Inc.), an integrated specialty pharmaceutical company. Prior to that, Mr. Boxer was a healthcare investment banker at Furman Selz. Mr. Boxer received a B.B.A. in Finance from Colorado State University and an M.B.A. from the University of Chicago Booth School of Business.

Andy is the founding partner of APG Partners, a private equity and advisory firm. He is also a founding partner of Acorn Dental Capital, an investment and advisory firm focused on emerging group dental practices. Andy has been a private equity investor for over 30 years.

Andy has served as Chairman, Board member or strategic advisor to Aspen Dental Management, Dental Partners, Pure Dental Brands, Access Health Dental, and TenBrook Orthodontics.

Andy received his B.A. from Dartmouth College and M.B.A. from the Amos Tuck School.

Dr. Kerslake is the CEO of Topera Medical (acquired by Abbott).

Prior to Topera, Dr. Kerslake was the Corporate Vice President, Portfolio Management at Boston Scientific and the Chief Operating Officer at MDdatacor, a cardiology/healthcare IT company.

Previously, he spent five years at The Monitor Group, a global strategy consulting firm based in Cambridge, MA. Before joining Monitor, Dr. Kerslake worked as Senior Scientist and Head of Formulation for Allergan (NYSE:AGN).

Dr. Kerslake holds an M.B.A. from the University of California, Irvine and a Ph.D. in Pharmaceutical Sciences–Drug Delivery from Cardiff University.